![Edward van der Horst](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edward van der Horst
Directeur Technique/Scientifique/R&D chez
FAETH THERAPEUTICS, INC.
Fortune : - $ au 31/08/2026
Profil
Edward van der Horst is currently Chief Scientific Officer at Sensei Biotherapeutics, Inc. since 2022, with employment at the company starting in 2019.
Formerly, Dr. van der Horst was Senior Director-Preclinical Development at Igenica Biotherapeutics, Inc. from 2010 to 2017 and VP-Discovery Biology & Preclinical Drug at Zenith Epigenetics Ltd. from 2017 to 2019.
Education includes graduate studies at Ludwig-Maximilians-Universität München and a doctorate from Max Planck Institute of Biochemistry.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Postes actifs de Edward van der Horst
| Sociétés | Poste | Début |
|---|---|---|
| FAETH THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 07/12/2022 |
Anciens postes connus de Edward van der Horst
| Sociétés | Poste | Fin |
|---|---|---|
Zenith Epigenetics Ltd.
 Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company | Corporate Officer/Principal | 01/08/2019 |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cancer | Corporate Officer/Principal | 01/01/2017 |
Formation de Edward van der Horst
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
34
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cancer | Health Technology |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Max Planck Institute of Biochemistry
 Max Planck Institute of Biochemistry Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company | Commercial Services |
Sensei Biotherapeutics, Inc.
 Sensei Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops immunotherapies for cancers and infectious disease | Health Technology |
